US FDA proposes new cGMP rules for combination products
This article was originally published in SRA
The US Food and Drug Administration plans to codify the current good manufacturing practice requirements for “single-entity” and “co-packaged” combination products because it believes that the absence of clear requirements for these products could result in inconsistencies affecting product safety and the public health1.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.